Synovial mesenchymal stem cells have a high proliferative and chondrogenic potential. Ten minutes after suspension of synovial stem cells is placed on a cartilage defect, most cells adhere to the defect and they promote cartilage and meniscus regeneration. These make it possible to regenerate cartilage and meniscus with low invasiveness.
Newly designed DNA plasmids encoding reprogramming factors, which enable efficient generation of human iPS cells from peripheral blood, cord blood, EBV transformed B cells and fibroblasts. Disease-specific iPS cells are useful for drug discovary.
Induction and purification of cardiovascular cell types, cardiomyocytes, endothelial cells and vascular mural cells, from human iPS cells. Then reconstituting cardiac tissues with cell sheet technology and applying to cardiac regenerative therapies and disease modeling.
We have developed a liver regeneration therapy with curative effects on liver cirrhosis by the infusion of mesenchymal stem cells isolated from a small amount of autologous bone marrow fluid aspirated under local anesthesia and expanded in Cell Prossesing Center (CPC). In parallel with this therapy, we will continue to develop the culture method including the cultivation equipment with safe and higher improvement effects.
We have succeeded in long-term self-renewal of human ES/iPS-derived hepatoblast-like cells by laminin 111 for large-scale preparation of hepatocyte-like cells. The generation of expandable hepatoblast-like cells would lead to the advantages below.
1. stable and abundant supply of hepatocyte-like cells for drug screening and hepatocyte transplantation
2. cost reduction in generating hepatocyte-like cells
3. elimination of residual undifferentiated pluripotent stem cells